Gregory Maes: Great EACR Liquid Biopsies 2024 meeting
Gregory Maes, Global Pharma and Strategic Alliances Manager at Nonacus, shared a post on LinkedIn:
“What a great EACR Liquid Biopsies 2024 meeting it was!
Thank you for joining Nonacus and stopping by our stand during the European Association for Cancer Research (EACR) conference in Lyon last week!
A big thank you to the organizers, Professor Caroline Dive. CBE, Nicola Aceto, Ellen Heitzer, Florent Mouliere and of course EACR conference organizer Hannah Barrs and her team for compiling all lectures, posters and social event together!
Our Nonacus team Agata Stodolna, PhD and myself (Gregory Maes) had a fantastic time!
As a precision medicine and liquid biopsy start-up, Nonacus focuses on precision and non-invasive healthcare technologies and has a mission to decentralise and democratise molecular testing for precision medicine and oncology.
Our freshly promoted Product Development and Compliance Manager Agata Stodolna, PhD was delighted to present our newly developed ESR1 ultrasensitive qPCR assay, allowing a faster, more sensitive and more cost-efficient detection of resistance mutations in the ESR1 gene associated with breast cancer (GALEAS uPCR ESR1)!
You can download a copy of her poster here and check all great features here.
We had the opportunity to meet some of our partners and customers, while enjoying discussions on the future of liquid biopsy with interested researchers, lab managers, LB companies, pharma leaders and clinicians!
We were also able to discuss in greater depth your interests and needs for innovative clinical solutions such as our high-precision NGS technology (for specific monitoring of patients in oncology, CDx, LBx or MRD) and, as well as other cfDNA pre-analytical solutions, perfectly suited to all liquid biopsy applications. Your interest was great in our complete solutions, under the name GALEAS, providing a complete pipeline from sample to bioinformatics/interpretation.
Developing a custom NGS panel has never been easier using our online panel design tool, which includes our enhanced library with the highest conversion rate on the market for multiple applications in precision oncology.
If you would like to discuss our innovative solutions and their implementation in your lab/diagnostics centre/company/drug development pipeline with CDx, please contact me (Gregory Maes) here or by email: [email protected].
For more information.
For some of you, see you next week in Barcelona for the European Liquid Biopsy Society (ELBS) General assembly, where we’ll showcase our newest bladder cancer clinical data using GALEAS Bladder!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023